ReviewDigestive diseases and sciences2020
Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases.
Review in Digestive diseases and sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed, 1 synthesis or guideline pooled it, 172 citations in OpenAlex.
- Safety and efficacy of fecal microbiota transplantation for autoimmune diseases and autoinflammatory diseases: A systematic review and meta-analysis.Frontiers in immunology · 2022Pooled it
- Fecal Microbiota Transplantation in Chronic Pouchitis: A Randomized, Parallel, Double-Blinded Clinical Trial.Inflammatory bowel diseases · 2021Trial
- Randomized Trial of Ciprofloxacin Doxycycline and Hydroxychloroquine Versus Budesonide in Active Crohn's Disease.Digestive diseases and sciences · 2021Trial
- Neglected kingdoms: the gut virome, mycobiome and their role in inflammatory bowel disease.Gut microbes · 2026Review
- Defined human Clostridia consortia reverse colitis via dual effects of tryptophan metabolites on microbiota and immunity.Cell host & microbe · 2026Article
- The Gut Microbiome in Pouchitis: A Narrative Review of Pathogenesis and Therapeutic Modulation.Nutrients · 2026Review
- From dysbacteriosis to ecological remodeling: A new breakthrough in microbial treatment of inflammatory bowel disease.iScience · 2026Review
- Fabrication of Colon-Targeted Delivery System of Astaxanthin Based on Bacteroides-Dependent Biodegradation Strategy and Its Role in Ameliorating DSS-Induced Colitis in Mice.Foods (Basel, Switzerland) · 2026Article
- Microbiome modulating remedies for chronic diseases: a review of current interventions and future directions.Inflammopharmacology · 2026Review
- [Advanced Combination Therapy in Inflammatory Bowel Disease].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2026Review
- Development of a Quantitative Serial LC-MS/MS Method for Gut Microbiota Metabolomics.ACS omega · 2026Article
- The AMP-antibiotic-microbiota triad in IBD: a mechanistic framework for dysregulated antimicrobial defense.Frontiers in immunology · 2026Review
- Future of inflammatory bowel disease treatment: A review of novel treatments beyond guidelines.World journal of methodology · 2025Review
- Article
- Advanced adhesion and targeting strategies to prolong gut residence time and improve eLBP efficacy in colonic diseases.Advanced drug delivery reviews · 2025Review
- Emerging microbiome-directed therapies in inflammatory bowel disease: beyond diet modification and FMT.Seminars in immunopathology · 2025Review
- Spontaneous mutant in threespine stickleback connects endosome trafficking disorders and inflammatory bowel diseases via changes in the gut microbiome.bioRxiv : the preprint server for biology · 2025Article
- Cystic fibrosis and inflammatory bowel disease: parallels in gut physiology and microbiota.Journal of bacteriology · 2025Review
- Microbial proteases as emerging anti-inflammatory therapeutics: a comprehensive review.Archives of microbiology · 2025Review
- Current paradigms in the management of inflammatory bowel disease.Singapore medical journal · 2025Article
44 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Inflammatory bowel diseases (IBD), including Crohn's disease, ulcerative colitis, and pouchitis, are chronic, relapsing intestinal inflammatory disorders mediated by dysregulated immune responses to resident microbiota. Current standard therapies that block immune activation with oral immunosuppressives or biologic agents are generally effective, but each therapy induces a sustained remission in only a minority of patients. Furthermore, these approaches can have severe adverse events. Recent compelling evidence of a role of unbalanced microbiota (dysbiosis) driving immune dysfunction and inflammation in IBD supports the therapeutic rationale for manipulating the dysbiotic microbiota. Traditional approaches using currently available antibiotics, probiotics, prebiotics, and synbiotics have not produced optimal results, but promising outcomes with fecal microbiota transplant provide a proof of principle for targeting the resident microbiota. Rationally designed oral biotherapeutic products (LBPs) composed of mixtures of protective commensal bacterial strains demonstrate impressive preclinical results. Resident microbial-based and microbial-targeted therapies are currently being studied with increasing intensity for IBD primary therapy with favorable early results. This review presents current evidence and therapeutic mechanisms of microbiota modulation, emphasizing clinical studies, and outlines prospects for future IBD treatment using new approaches, such as LBPs, bacteriophages, bacterial function-editing substrates, and engineered bacteria. We believe that the optimal clinical use of microbial manipulation may be as adjuvants to immunosuppressive for accelerated and improved induction of deep remission and as potential safer solo approaches to sustained remission using personalized regimens based on an individual patient's microbial profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.